Share this video  

GU Cancers 2023 | The potential of radiopharmaceuticals for the treatment of prostate cancer

Anthony Victor D’Amico, MD, PhD, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, explains the current role that radiopharmaceuticals have in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC). Prof. D’Amico also discusses the limitations and risks of using radiopharmaceuticals and how to overcome these challenges. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.